
Revolutions and Resolutions— Some Perspectives for 2008

Christopher Joneckis, Ph.D.
Center For Biologics Evaluation and Research
June 27, 2008, BIO, San Diego

Critical Products for Public Health, National Preparedness & 21st Century Medicine




Blood Derivatives

Vaccines



Whole Blood

Blood Components



Somatic Cell & Gene Therapy



Allergenic Extracts



Devic

Tissues

Xenotransplantation



- Change and excitement
- Some major directions/thoughts
- Strive to envision and seek opportunities not fight them
- Though much is possible, nothing is simple...yet
- Enabling collaboratively and globally early and throughout development and manufacturing
- Common goals improve US and global health

Change and Excitement – Just a Few Examples

- Targeted and Personalized Medicine
- Repair or replace, not just treat stem cells, gene therapy, tissue engineering
- Prevention, primary and secondary, including cancer
- Global and Public Health increased needs and valuation
- Large Databases for Safety and Utility

1- Hit The Target

Right Target in Right Person – Biomarkers – Critical Path

- Biomarkers can help identify promising (or risky) pathways, leads, responses, dosing etc.
- Goal more effective/safer therapy, more efficient and less costly development
- What's not simple
 - Most biomarkers not surrogates but still can be useful – right patient/right drug
 - Business models, costs
 - Pathway targets/actions may also be good
 - There is probably some reason that you name it (gene, protein, polymorphism) is there, and it is possible that even the most targeted therapy will mess something up
 - » Examples TNF and infection, cox-2

Resolutions

- FDA promoting biomarker research, validation
- Biomarker Consortium FNIH-NIH-FDA-Academia-Industry collaboration
- OBQI FDA/NIH/NCI/CMS collaboration
- Pharmacogenomic safety
 - CBER biologics genomics initiative
- Pandemic, anthrax correlates
- Critical Path Research (CBER biomarkers on stem cells, cell substrate quality, vaccine, adjuvant and blood product efficacy and toxicity)

Role of Science and Critical Path

- CBER reviewers and research-reviewers identify solutions to product development challenges
 - expert in biological product evaluation AND standard scientific disciplines
 - Big Picture" rapidly identify successes, failures, and missed opportunities across whole classes of exciting and innovative products
 - work for the American Public w/o conflicts and play a convening and coordinating role for scientific needs across sponsors
 - collaborative & Leveraging: internal and external resources
 - focus is unique: research managed to identify solutions to product development challenges
- Creating efficient, high quality regulatory pathways where there are none
- Applying 21st Century science to improve efficiency and predictability of established regulatory pathways

FY08 Research Priorities - 1*

- Improve or develop new methods to measure and augment biological product safety and efficacy.
- Evaluate, develop, integrate novel scientific technologies to improve biologics product regulatory pathways, availability, quality.
- Facilitate the development of new biological products for high priority public health threats, including pandemic influenza, emerging infectious diseases, and agents of bioterrorism.

FY08 Research Priorities - 2

- Improve clinical trial design and evaluation, including adaptive design approaches
- Develop formal risk management and risk assessment approaches
- Enhance safety surveillance by developing improved analytical tools and accessing large databases (CDC, Medicare, etc)


Biomarkers - Genomics/Microarray: Application to Cellular & GeneTherapy

- Ability to assess quality of cell substrates
 - Identification of genes signatures as biomarkers for quality of cell products (e.g., confluence status, comparabilty)
- Biomarkers for biological product characterization (purity, identity, potency)
 - rapid detection and identification of viral and bacterial pathogens
- Identification of unique product characteristics linking to clinical outcome good or bad


Characterization of Stem Cell Therapies by Genomics/Microarray

In collaboration with NIH, Academia and Industry, CBER scientists developed a method and identified gene biomarkers expressed in several stem cell lines


Ongoing communications with stakeholders to develop standards to compare results across different platforms and across different clinical sites



Genomics/Microarray: Application to Mycoplasma Detection




2 - Repair/replace! - New Sources of Stem Cells




Development of Human cloned Blastocysts Following Somatic Cell Nuclear Transfer (SCNT) with Adult Fibroblasts – French et al, Stem Cells, 2008

Or...Reprogram




Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells Junying Yu, Maxim A. Vodyanik, Kim Smuga-Otto, Jessica Antosiewicz-Bourget, Jennifer L. Frane, Shulan Tian, Jeff Nie, Gudrun A. Jonsdottir, Victor Ruotti, Ron Stewart, Igor I. Slukvin, and James A. Thomson *Science* December 2007

or...Remake the Target – Bioengineered Heart Valve



OR A NEW HEART???



What's Not Simple?

- Fate/oncogenesis of genes/cells/tissues
- Differentiation/functionality/regulation
- Host environmental effects on new cells/tissues, functionality, survival
- Boundaries, ethics, unforeseen risks?
- Resolutions:
 - proactive workshops, AC's to define issues/pathways, study designs etc.
 - examples cell scaffolding, islet, cartilage, cardiac cell Rx, MATES, discussion of ESC science issues
 - Collaborative CP science e.g. NTP study

Enabling New Technologies: Approaches and Resolutions

- We will continue to enable and develop our:
 - Science base: nurture, sustain, collaborate
 - Multidisciplinary & Integrated review & inspection teams
 - Life cycle approach multidisciplinary safety teams, risk assessment/risk based approaches in manufacturing, compliance and for regulatory decisions
 - Early and continued interactions with sponsors: include manufacturing and product characterization
 - Interaction with 3rd party standards organisations
 - Open to new approaches, tools, your help!

Participation in Standards Development Organizations

- FDA Standards Policy
- In 2007
 - ~100 staff participated in ~75 stds development activities with ~30 organisations in all product areas
- Organizations include:
 - Accredited voluntary consensus standards organizations (e.g., ASTM, ISO, HL-7)
 - Industry, Trade Groups (e.g., ISCT, AABB, AATB)
 - International (e.g., ICH, GHTF, WHO/ECBS, PAHO, NIBSC, PEI, TGA)
- ASTM Subcommittee on Cell Signaling (F04.46)
 - Accurate and quantitative measurements of cell signaling biomarkers, aided by reference materials and standards
 - Global impact on scientific understanding, R&D, QA/QC

FDAs Bioinformatics

- Centralization of information management and many information systems across FDA
- Electronic environment advantages & challenges
- Sensitivities e.g., transition time, small entities, participation of users
- Standards development crucial— ICH, HL-7
- Ensuring capability for 21st technologies
 - Designing for scientific computing

3 - Prevent or Intervene Early

- Classic vaccine strategy
 - Revolutions prevention of cervical, hepatocellular cancers
- Increased interest in early use of therapeutics
- What's not simple?
 - Scientific challenges (e.g. malaria, TB, cancer immunology)
 - Duration and cost of large, prolonged clinical trials, other market issues
 - Potential risks to healthy
- Resolutions: cancer vaccine workshops, adjuvant science, new biomarkers, initiatives for prevention

4 - Globalization and Public Health-Needs and Opportunities

- Humanitarian needs and value
- Disease threats global, no boundaries
 - Pandemic flu, HIV, malaria, TB (including drug resistance) – I'd get a safe TB vaccine
 - And don't forget diseases of 'progress' emerging threats as nations develop
- Manufacturing, knowledge and regulation are global
- Needs, markets and opportunities are global

What's Not Simple

- Markets uncertain or 'insufficient'
- Examples in US and globally
 - Uncertainty emerging diseases, bioterrorism
 - Insufficient segmented blood diagnostics, antibiotics especially for resistant organisms
 - Value to public health and preparedness not directly economically linked – incentives/push/pull
 - But recent successes with vaccine industry
- Delivery systems and sustainability
- Resolutions: Intense FDA/CBER input and support for BioShield/BARDA and influenza projects, other priority public health projects (e.g. WNV) – global leadership, information sharing, quality, scientific and regulatory collaboration and convergence
- Challenges with increasing collaboration, increasing demands upon CBER resources

Resolutions - Global Harmonization & Collaboration: Examples


- Emerging Threat Preparedness Leadership FDA/WHO/Health Canada Pandemic Regulators
- WHO and WHO Collaborating Center, PAHO
 - ECBS, SAGE, GCVS, influenza, xeno and gene therapy
 - Regulatory capacity building/assistance
- Blood: GCBS leadership, WHO "Circle of Regulators"
- ICH (including GT), PIC-S, ICDRA
- Information sharing + support global product development plans/coordinated regulation
 - EMEA, HC, TGA, PEI, others
- CBER Global Vaccine Initiative
 - Consultation, standards, CP science, reg. capacity
 - MVI, Gates, TB, PATH, meningitis, etc.

Safety and Value: New Approaches

- Safety is not absolute: need for transparency and better, early communication, "risk literacy"
 - Benefits & risks both considered
 - Patient & consumer trust/confidence
- CBER multidisciplinary teams
 - Increased use of large datasets
 - Consistent with IOM, FDAAA
- Value of improved safety approaches will be rewarded
 - Prevention, improved therapies, not marginal gains
 - Challenges in measurement:
 - Should consider not just value to health systems but also
 - To individual and.....to public welfare, society and health
 - Large datasets can help with some of this, as well

CBER's Safety Teams

- Tissue (2004), Blood (2006), Vaccine (2007)
 - Multidisciplinary and collaborative each includes product, manufacturing, safety, clinical, compliance, and communication experts – all share common data
 - Meet at least monthly, IOD participates, entire team also meets quarterly with Center Director/Deputy – can be immediately convened in any emerging/urgent situation
 - Structured interfaces with ORA, CDC, others as appropriate
- Goals/accomplishments:
 - Proactively and rapidly identify and address significant ongoing and emergent safety issues
 - Serve as focus for developing and implementing longer term priorities, innovative practices and collaborations, and quality improvement
 - Enhance internal and external communication and collaboration (including public, rest of FDA, CDC, HRSA, international/WHO etc.)



What's Not Simple?

- Quality and format of data from health systems variable at best
- Analytic tools and approaches not yet up to data quantity and variability
 - Clusters false positives
 - Lack of background rates
 - Confounding is abounding
- Communication of risk and of uncertainty
- Resolutions partnerships e.g. FDA/RUF
 - CBER: Data Analytic Unit, CDC VSD, CMS,
 VA, DMSS, enhanced early communication
- HHS Sentenial Initiatives

Knowledge, Risk, & Oversight

- Increasing complexity results in increasing unknowns – applicable in many areas
- Effective Understanding for Appropriate Regulation
 - Scientific foundation will need to be established and effectively communicated
 - Risk will have to be appropriately assessed, managed and communicated
 - Product Quality & Safety will need appropriate oversight
- Early and continued interactions with sponsors/ manufacturers and integration of review and CGMP issues has proven beneficial, particularly when complex and/or innovative technologies are proposed in facilitating product development and improvement

"Risk Literacy"

- Risk literacy difficult and non-intuitive to understand risk and causal association statistically vs. individually
- There are risks in conveying uncertainties, including potential decreased use of safe product, public health consequence if vaccine
- Major behavioral science, educational system and risk communication science needs (FDA AC)

2008 CBER Priorities

- Pandemic/emerging threat preparedness
- Enhance product safety and confidence
 - Interdisciplinary safety teams, FDAAA, new sources and approaches to data, better communication
- Improve manufacturing and product quality
 - Risk based and preventive compliance, product testing, assay, standards development, CMC QS
- Innovative, safe, effective products to patients
 - Critical Path, Tissue Engineering Team, Blood Cell Preservation, Genomics, Research Management
- Strengthen human and organizational resources
 - Recruitment, succession planning, continual process improvement system, staff competencies &training
- Global public health and globalization
 - Products for public health needs, Global Vaccine Initiative, product and supply chain quality/availability, harmonization and collaboration

Thank you!

- We are poised for and embrace many revolutions and changes
- Value will be rewarded and includes, but is not limited to, safety, effectiveness and quality
- Collaboration and best science essential work together ahead of curve
- Challenge us and yourselves!
- We will work with stakeholders to go from "good to great"
- Individual, global and public health can and must benefit

www.fda.gov/cber

Contact OCTMA@CBER.FDA.GOV 301-827-1800

CBER: INNOVATIVE TECHNOLOGY ADVANCING PUBLIC HEALTH